Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674536 | SCV000799888 | pathogenic | Cobalamin C disease | 2018-05-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000674536 | SCV000958795 | pathogenic | Cobalamin C disease | 2024-02-25 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr205*) in the MMACHC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 78 amino acid(s) of the MMACHC protein. This variant is present in population databases (no rsID available, gnomAD 0.06%). This premature translational stop signal has been observed in individuals with combined methylmalonic aciduria and homocystinuria (PMID: 16311595, 19914430, 20631720, 25388550). ClinVar contains an entry for this variant (Variation ID: 558292). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000674536 | SCV001162919 | pathogenic | Cobalamin C disease | criteria provided, single submitter | clinical testing | ||
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000674536 | SCV002015072 | pathogenic | Cobalamin C disease | 2021-10-25 | criteria provided, single submitter | clinical testing | Variant summary: MMACHC c.615C>A (p.Tyr205X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 249538 control chromosomes. c.615C>A has been reported in the literature in individuals affected with Cobalamin C Disease (Methylmalonic Aciduria With Homocystinuria, e.g. Hu_2018, Zhang_2020). These data indicate that the variant may be associated with disease. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Genome- |
RCV000674536 | SCV004178210 | pathogenic | Cobalamin C disease | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Juno Genomics, |
RCV000674536 | SCV005417440 | pathogenic | Cobalamin C disease | criteria provided, single submitter | clinical testing | PM2_Supporting+PVS1_Strong+PM3_VeryStrong+PP4 | |
Fulgent Genetics, |
RCV000674536 | SCV005654948 | pathogenic | Cobalamin C disease | 2024-06-06 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001275216 | SCV001460140 | pathogenic | Methylmalonic acidemia with homocystinuria cblC | 2020-09-16 | no assertion criteria provided | clinical testing |